瑞舒伐他汀和阿托伐他汀治疗冠心病的疗效及安全性研究

Analysis of the safety of rosuvastatin and atorvastatin in the treatment of coronary heart disease

目的:对比分析瑞舒伐他汀与阿托伐他汀治疗冠心病的安全性与疗效。方法:2018年2月-2019年10月收治冠心病患者101例,随机分为两组。两组患者入院后均接受硝酸酯类、β受体阻滞剂、抗血小板药物等基础治疗,研究组采用瑞舒伐他汀治疗,对照组采用阿托伐他汀治疗。比较两组患者临床疗效、用药期间不良反应发生率、用药前后左心射血分数及血脂指标水平。结果:研究组用药后血脂各项指标水平均优于对照组,差异有统计学意义(P<0.05);研究组用药后左心室射血分数高于对照组,差异有统计学意义(P<0.05);研究组不良反应发生率低于对照组,差异有统计学意义(P<0.05);研究组治疗总有效率高于对照组,差异有统计学意义(P<0.05)。结论:采用瑞舒伐他汀治疗冠心病的效果更佳,且用药安全性高于阿托伐他汀。

Objective:To compare and analyze the safety and efficacy of rosuvastatin and atorvastatin in the treatment of coronary heart disease.Methods:From February 2018 to October 2019,101 cases of patients with coronary heart disease were enrolled,they were randomly divided into two groups.Both groups were treated with nitrates,βreceptor blockers and antiplatelet drugs after admission.The study group was treated with rosuvastatin,while the control group was treated with atorvastatin.The clinical efficacy,incidence of adverse reactions,left ventricular ejection fraction and blood lipid index level before and after medication between two groups were compared.Results:The various indicator levels of blood lipids in the study group were better than those in the control group,the differences were statistically significant(P<0.05).Left ventricular ejection fraction in the study group was higher than in the control group,the difference was statistically significant(P<0.05).The incidence of adverse reactions in the study group was lower than that in the control group,the difference was statistically significant(P<0.05).The total effective rate of treatment in the study group was higher than that in the control group,the difference was statistically significant(P<0.05).Conclusion:Rosuvastatin is more effective in the treatment of coronary heart disease and the safety of medication is higher than atorvastatin.